AstraZeneca plc 13.6% Potential Upside Indicated by Barclays Capital

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc with EPIC/TICKER (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OVERWEIGHT’ this morning by analysts at Barclays Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set their target price at 7000 GBX on its stock. This now indicates the analyst believes there is a possible upside of 13.6% from the opening price of 6160 GBX. Over the last 30 and 90 trading days the company share price has decreased 52 points and increased 303 points respectively. The 1 year high for the share price is 6540 GBX while the year low share price is currently 4825 GBX.

AstraZeneca plc has a 50 day moving average of 6,067.80 GBX and a 200 Day Moving Average share price is recorded at 5,920.04. There are currently 1,267,287,658 shares in issue with the average daily volume traded being 2,553,151. Market capitalisation for LON:AZN is £79,484,281,909 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

      Search

      Search